Polyrizon News

News

Ticker

PLRZ

ISIN

IL0011814113

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Polyrizon Eulerpool News

Polyrizon Stock News

Polyrizon is being monitored by journalists and investors worldwide. We gather the latest Polyrizon news here.

March 17·
Benzinga
Polyrizon Signs Deal With Contract Research Organization To Carry Out Package Of Preclinical Biocompatibility Studies In Accordance With ISO 10993 Standards, GLP Requirements
March 10·
Benzinga
Polyrizon Announces Production Of Good Manufacturing Practice Batch Of Clinical Trial Material For Its Lead Product Candidate
February 26·
Yahoo
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
February 26·
Benzinga
Polyrizon Announces Results From Comparative Study Evaluating Regional Nasal Deposition Profile Of Naloxone Formulation Versus Commercial Reference Product
February 17·
Yahoo
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
February 13·
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
February 10·
Yahoo
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
February 6·
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
February 6·
Yahoo
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
February 6·
Benzinga
Clearmind Engages Polyrizon To Apply Proprietary Intranasal Hydrogel Technology To Develop Optimized Formulation Of Clearmind's MEAI For Treatment Of Addiction-Related Disorders, Weight Loss And Other CNS Conditions
February 4·
Yahoo
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
January 29·
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 22·
Yahoo
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
January 14·
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 13·
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 13·
Yahoo
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
January 13·
Benzinga
Polyrizon Announced That Its Board Of Directors Has Authorized The Exploration Of Strategic Investment Opportunities In Select Revenue-Generating Assets; Efforts Include Defense, Aviation And AI Assets While Advancing Its Intranasal Medical Pipeline
January 8·
Yahoo
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
January 8·
Benzinga
Polyrizon Completes Branding Of PL-14 Allergy Blocker As NASARIX, Advancing Commercial Readiness
January 5·
Yahoo
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Polyrizon Stock Press Releases

Polyrizon regularly publishes news on the company's website that are relevant for investors.

Polyrizon News 2026

This page contains all current news, analysis and press releases for Polyrizon stock (PLRZ, ISIN: IL0011814113). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Polyrizon.

Polyrizon Stock

Polyrizon Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements.